卞慧敏

发布者:花文婷发布时间:2022-10-27浏览次数:331

职称:研究员      E-mailhmbian@sina.com   

主要研究方向:主要从事中药及复方抗心脑血管疾病的作用及其机理研究,以及中药新药临床前药理毒理研究。

 

个人简介

       研究员,博士生导师。现为江苏省中药药效与安全性评价重点实验室、江苏省优势学科中药药理学科和国家中医药局三级实验室心脑血管药理方向学术带头人、中国药理学会中药与天然药物药理专业委员会委员、中华中医药学会实验药理专业委员会常务委员,世中联中药上市后再评价专业委员会理事,国家食品药品监督管理局新药评审专家、保健食品评审专家、江苏省食品药品监督管理局药品、保健食品评审专家。国家科学技术奖、教育部科技成果、国家自然科学基金、多个省级基金及科技奖等评审专家。1997年被选为跨世纪人才(333工程)第三层次培养对象。近五年来主持和参加了二十余项国家级、部省级、厅局级课题及企业委托项目的研究,其中十余项课题已完成并通过鉴定,多数经专家认定处于国内领先水平。作为药理毒理研究负责人获得中药新药临床批件10项,获得各类成果奖11项。作为副主编参加编写出版了《中药药理学》《血管生成研究方法与技术》。以第一作用和通讯作者发表科研论文100余篇,其中SCI收载30余篇。

 

承担的主要科研项目

国家自然科学基金面上项目(81774029),基于雌激素受体甲基化的分子调控探讨六味地黄方抗更年期AS的作用机制,2018/01-2021/12,主持,55.0万元,结题。

国家自然科学基金面上项目(82274243),基于补不足损有余理论探讨“熟地-泽泻”药对调节肠道α-防御素重塑肠道菌群改善绝经后动脉粥样硬化的机制,2023/01-2026/12,主持,51.0万元,在研。

国家自然科学基金面上项目(81873007),基于水液转运蛋白调控研究大戟属有毒中药醋制“毒-效”转化的共性机制,2019/01-2022/12,主要参与者,56.0万元,在研。

 

代表性论文

1.Qinghai Menga, YuLi,Tingting Ji,Ying Chao,Yu Fu,SuyunWang,Qi Chen, WenChen, FuhuaHuang, YouranWang,Qichun Zhang, XiaoliangWang*,Huimin Bian*.Estrogen prevent atherosclerosis by attenuating endothelial cell pyroptosis via activation of estrogen receptor α-mediated autophagy .Journal of dvanced Research Available 282021149~164.(IF10.4)

2.Qinghai Meng,Menghua Ma,Weiwei Zhang,Yunhui Bi,Peng Cheng, XichaoYu, Yu Fu, Ying.Chao , Tingting Ji, Jun Li, Qi Chen, Qichun Zhang,Yu Li, Jinjun Shan*, Huimin Bian*.The gut microbiota during the progression of atherosclerosis in the perimenopausal period shows specific compositional changes and significant correlations with circulating lipid metabolites. Gut Microbes. 2021,VOL.13,NO.1,1-27.(IF10.2)

3. Qinghai Menga,Jun Li,Ying Chao, unhui Bi,Weiwei Zhang,Yuhan Zhang, Tingting Ji,Yu Fu,Qi Chen ,Qichun Zhang,Yu Li*,Huimin Bian*.β-estradiol adjusts intestinal function via ERβ and GPR30 mediated PI3K/AKT signaling activation to alleviate postmenopausal dyslipidemia. Biochemical Pharmacology 180 (2020) 114134.(IF4.96)

4. Qi Chen,Xu Qi,Weiwei Zhang, Yuhan Zhang ,Yunhui Bi,Qinghai Meng ,Huimin Bian*,Yu Li* .Catalpol Inhibits Macrophage Polarization and Prevents Postmenopausal Atherosclerosis Through Regulating Estrogen Receptor Alpha. Frontiers in Pharmacology.April 2021 | Volume 12 | Article 655081.(IF5.81)

5.Jun Li,Qinghai Meng,Yu Fu,Xichao Yu,Tingting Ji,Ying Chao,Qi Chen,Yu Li*,Huimin Bian*. Dynamic foam cell driven from macrophage in Atherosclerosis. Journal of Cellular Physiology.28 January 2021.IF6.38

6.Yu Fu , Han Feng, Xue Ding, Qing-Hai Meng,Shu-Rui Zhang, Jun Li,Ying Chao, Ting-Ting Ji ,Yun-Hui Bi, Wei-Wei Zhang, Qi Chen,Yu-Han Zhang ,You-Long Feng*, Hui-Min Bian*. Alisol B 23-acetate adjusts bile acid etabolisim via hepatic FXR-BSEPsignaling activation to alleviate atherosclerosis. Phytomedicine 101 (2022) 154120IF6.656

7.Liang Wang, Hui Shic, Chun-chunZhao, Jing-ya Li,Jian-fei Peng,An-lu Shen,Peng Zhou*, Hui-min Bian*.Astragaloside IV protects diabetic cardiomyopathy against inflammationand apoptosis via regulating TLR4/MyD88/NF-κB signaling pathway. Journal of Functional Foods. Journal of Functional Foods 88 (2022) 104905IF5.223

8.Chen Q, Zhang Y, Meng Q, Wang S, Yu X, Cai D, Cheng P, Li Y, Bian H, Liuwei Dihuang prevents postmenopausal atherosclerosis and endothelial cell apoptosis via inhibiting DNMT1-medicated ERalpha methylation[J]. J Ethnopharmacol, 2020. 252: 112531.IF3.69

9. Xi-Chao Yu , Yu Fu ,Yun-Hui Bi,Wei-Wei Zhang,Jun Li,Ting-Ting Ji, Ying Chao,Qing-Hai Meng,Qi Chen,Meng-Hua Ma,Yu-Han Zhang,Jin-Jun Shan*,Hui-Min Bian* .Alisol B 23-acetate activates ABCG5/G8 in the jejunum via the LXRα/ACAT2 pathway to relieve atherosclerosis in ovariectomized ApoE -/- mice.Aging-US.2020, Vol. 12, No. 24:25744-25766.IF4.831

10. Qi Chen, Ying Chao, Weiwei Zhang, Yuhan Zhang, Yunhui Bi, Yu Fu, Danfeng Cai, Qinghai Meng, Yu Li and Huimin Bian*.Activation of estrogen receptor α (ERα) is required for Alisol B23-acetate to prevent post-menopausal atherosclerosis and attenuate lipid accumulation. Life Sciences. Volume 258, 2020.(IF3.647).


 

 




南中医澳门新葡官网进入网站8883南中医澳门新葡官网进入网站8883学子
Baidu
sogou